It is time for Milby and Co. to deliever something ----we have had mark approval for over a year.
Hopefully we get news on:
1) FDA trial submission
2) One or more commercial deals in EU, Asia or ME
3) The launching of a lawsuit vs. Tauropharm
4) Label expansion efforts
5) A (Wall Street) coverage pick-up or two
Concur with your sentiments. I guess we have breast, melanoma and (don't forget) SCLC data due at some point. Very hard to understand this company from the outside. I really wish they would do an in-depth investors' day and bring Kirk in to share his vision. I remain hopeful that the Intrexon platform has created value over the last 3 years and some Big Pharma with deep pockets will help move the programs forward. They have discussed 8 potential INDs short term but ZIOP is far too small and thinly capitalized to go it alone. We need a deal to validate the technology and firm up the balance sheet. IF, IF, IF that transpires, the squeeze would be EPIC (Humongous? Ginormus?) .
Nice to see. Hopefully CEO Milby finally inks the long awaited deal. BTW, do we have any sales in ME yet? CMON guys!!!!!!!!!!!!!!!
Execution here has been problematic to say the least. They were almost a year late on obtaining the CE approval and a year after said approval CRMD has negligible sales to date. Hopefully the new BOD members will inject the missing talent/effort/focus/??? into the equation. Recent proxy vote likely hints at a certain level of frustration. Elliot will not wait forever.
Withholding judgement until the next CC. The FDA side appears to be progressing. Progress re: the commercialization effort is an an unknown at this point.
Fully understand your point but I would counter that partnering with a large EU partner who could roll over TP is preferable since historically trying to merge with a private entity is difficult since the financials are often questionable and private owners tend to overvalue their franchise. TP cannot sell to anyone else based on the IP issue so what is the franchise really worth? Perhaps giving them a minority interest in CRMD in return for revenue streams and utilizing them as a long term manufacturer with a negotiated margin is a possibility. Buying them out----NO. I also suspect there may be all kinds of skeletons in TPs financial/legal closet. You would have to do an asset swap (stock for sales?)of some sort as opposed to a merger.
The Germans likely do not want paper (stock) but again, who the heck do they sell the franchise to ??? TP has stolen enough over the years already. .
#4 is the value driver. Clean IND will likely lead to trial partnering. 10% chance partnering talks will move onto larger discussion of owning the cow as opposed to a % of milk sales. Becton, Baxter, Amgen, Abbot all good fits. This is a catheter care company, not simply a dialysis play so hopefully they stay out of the clutches of Fresenius. When the heck are they going to go after Tauropharm. IP theft should not be permitted to continue for YEARS. CMON--ask Elliot for a wee bit of help. Elliot has attack dogs that eat Rottweilers for fun. Could we borrow them for a trip to the Fatherland. Surely, they could decimate a small privately held entity controlled by 3 guys from Germany.
This is the downside of a small comopany. They have done much with few hands over the past 2 years but now it is time to execute. Mark approval is almost 1 year old and to date they have booked $24,000 in reported sales. Time to produce. My hope is that we get some news on the FDA front SOON.
Sorry. I believe MarkAk is correct. The delisting issue is technical and based upon positions held by Elliot and Kingsbrook. Both have a vested interest to keep liquidity in the issue.
Lots to look forward to on FDA front and (hopefully) commercial aspects of EU. . I suspect they want to get something done short term or it could be a contentious annual meeting/BOD vote. Q2 is over in 3 weeks. Where the heck are our distribution deals???
I was hoping for an update on FDA progress and (per the CEO comments on the last 2 CCs) a distribution deal or two to be announced in the EU. The end of Q2 is weeks away and we have yet to hear a peep. Frustrating .
Is anyone planning on attending the annual meeting?
I was invested with these guys years ago in IOMAI. They are an able and trustworthy team. Bought a few today and will be adding in the coming weeks.